Fragrance-free and simple, its gentle on sensitive skin
In 2019, ESC guidelines recommended the use of SGLT2 inhibitors or GLP-1 RAs as first-line drugs in CV patients at high or very high risk with T2DM who do not receive any glucose-lowering treatment and the addition to current glucose-lowering therapy of SGLT2 inhibitors or GLP-1 RAs in those patients regardless of glucose control (Figure 3),18
Laboratory Testing: Full metabolic panel (glucose, HbA1c, lipids), inflammatory markers (CRP, IL-6), vitamin D and B12 levels, and complete blood count (CBC) to rule out nutritional or systemic contributors
Group Workouts Semaglutide & Tirzepatide Group Workouts Support cellular health, mental clarity, and natural energy production with our targeted NAD+ injections, designed to promote healthy aging, metabolic function, and overall wellness
Nat Rev Endocrinol (2023) 19(4):20116
503B vs 503A: do you know the difference